Novartis Reply to the ATMOSPHERE Data Monitoring Committee
| Autor: | R. Paul Aftring, Gervais Tougas |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
business.industry
General Medicine 030204 cardiovascular system & hematology Aliskiren Atmosphere (architecture and spatial design) medicine.disease 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine chemistry Medicine Data monitoring committee In patient 030212 general & internal medicine Medical emergency business |
| Zdroj: | New England Journal of Medicine. 374:1586-1587 |
| ISSN: | 1533-4406 0028-4793 |
| DOI: | 10.1056/nejmc1603515 |
| Popis: | To the Editor: The Sounding Board article by Swedberg and colleagues,1 now published in the Journal, describes the experience of the data monitoring committee of the Aliskiren Trial to Minimize Outcomes in Patients with Heart Failure (ATMOSPHERE) as data from other trials of aliskiren raised questions regarding a possible risk to participants in ATMOSPHERE.2 Novartis, as the sponsor of ATMOSPHERE, had engaged the independent data monitoring committee, which was composed of respected experts, to oversee the participants’ safety in this trial through periodic reviews of unblinded safety and efficacy data. During the course of the trial, the data monitoring committee, . . . |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|